Trials / Terminated
TerminatedNCT00506519
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn® (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to explore the efficacy and safety of ATryn® (antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by continuous intravenous (IV) infusion over five days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antithrombin alfa (INN name) | |
| DRUG | Control (Standard treatment) |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2007-07-25
- Last updated
- 2025-03-07
- Results posted
- 2021-08-31
Source: ClinicalTrials.gov record NCT00506519. Inclusion in this directory is not an endorsement.